File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/TP.0b013e3182a339a7
- Scopus: eid_2-s2.0-84889878587
- PMID: 23924774
- WOS: WOS:000330435400015
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts
Title | Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts |
---|---|
Authors | |
Keywords | Hepatocellular carcinoma Liver transplantation Grafts |
Issue Date | 2013 |
Citation | Transplantation, 2013, v. 96, n. 11, p. 995-999 How to Cite? |
Abstract | BACKGROUND: As a new scheme at our center, a Model for End-stage Liver Disease score of 18 points is assigned to candidates of deceased-donor liver transplantation (DDLT) who have hepatocellular carcinoma (HCC) remaining at stage 2 six months after their disease has been confirmed stage 2 HCC. Two points are added every 3 months if their disease remains at stage 2 or below. This study evaluated patient and tumor characteristics as well as surgical and short-term outcomes of DDLT in these patients. METHODS: Comparison of survival was made among three groups of patients who underwent liver transplantation (LT) in the same period. Group 1 consisted of 22 HCC patients who received DDLT under the new scheme. Group 2 consisted of 18 HCC patients who underwent living-donor LT. Group 3 consisted of 52 patients who underwent DDLT because of liver failure, among whom 6 had HCC but were not included in the new scheme. RESULTS: Group 1 had a median follow-up period of 17.9 months, and the 1-, 3-, and 5-year overall survival rates were 100%, 100%, and 80%, respectively. Group 2 had the corresponding rates at 100%, 100%, and 100% with a median follow-up of 19.6 months. Group 3 had the corresponding rates at 96.1%, 96.1%, and 96.1% with a median follow-up of 19.4 months. CONCLUSIONS: The policy of a 6-month wait has benefited the HCC patients who practically had no chance of undergoing living-donor LT. Their survival outcomes will be excellent as long as they can stand the test of time. © 2013 by Lippincott Williams & Wilkins. |
Persistent Identifier | http://hdl.handle.net/10722/221353 |
ISSN | 2023 Impact Factor: 5.3 2023 SCImago Journal Rankings: 1.371 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, SC | - |
dc.contributor.author | Sharr, WW | - |
dc.contributor.author | Chok, KSH | - |
dc.contributor.author | Chan, ACY | - |
dc.contributor.author | Lo, CM | - |
dc.date.accessioned | 2015-11-18T06:09:05Z | - |
dc.date.available | 2015-11-18T06:09:05Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Transplantation, 2013, v. 96, n. 11, p. 995-999 | - |
dc.identifier.issn | 0041-1337 | - |
dc.identifier.uri | http://hdl.handle.net/10722/221353 | - |
dc.description.abstract | BACKGROUND: As a new scheme at our center, a Model for End-stage Liver Disease score of 18 points is assigned to candidates of deceased-donor liver transplantation (DDLT) who have hepatocellular carcinoma (HCC) remaining at stage 2 six months after their disease has been confirmed stage 2 HCC. Two points are added every 3 months if their disease remains at stage 2 or below. This study evaluated patient and tumor characteristics as well as surgical and short-term outcomes of DDLT in these patients. METHODS: Comparison of survival was made among three groups of patients who underwent liver transplantation (LT) in the same period. Group 1 consisted of 22 HCC patients who received DDLT under the new scheme. Group 2 consisted of 18 HCC patients who underwent living-donor LT. Group 3 consisted of 52 patients who underwent DDLT because of liver failure, among whom 6 had HCC but were not included in the new scheme. RESULTS: Group 1 had a median follow-up period of 17.9 months, and the 1-, 3-, and 5-year overall survival rates were 100%, 100%, and 80%, respectively. Group 2 had the corresponding rates at 100%, 100%, and 100% with a median follow-up of 19.6 months. Group 3 had the corresponding rates at 96.1%, 96.1%, and 96.1% with a median follow-up of 19.4 months. CONCLUSIONS: The policy of a 6-month wait has benefited the HCC patients who practically had no chance of undergoing living-donor LT. Their survival outcomes will be excellent as long as they can stand the test of time. © 2013 by Lippincott Williams & Wilkins. | - |
dc.language | eng | - |
dc.relation.ispartof | Transplantation | - |
dc.subject | Hepatocellular carcinoma | - |
dc.subject | Liver transplantation | - |
dc.subject | Grafts | - |
dc.title | Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/TP.0b013e3182a339a7 | - |
dc.identifier.pmid | 23924774 | - |
dc.identifier.scopus | eid_2-s2.0-84889878587 | - |
dc.identifier.hkuros | 220305 | - |
dc.identifier.volume | 96 | - |
dc.identifier.issue | 11 | - |
dc.identifier.spage | 995 | - |
dc.identifier.epage | 999 | - |
dc.identifier.isi | WOS:000330435400015 | - |
dc.identifier.issnl | 0041-1337 | - |